Takeda Pharmaceutical
309 hedge funds and large institutions have $1.98B invested in Takeda Pharmaceutical in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 76 increasing their positions, 100 reducing their positions, and 41 closing their positions.
13% more capital invested
Capital invested by funds: $1.76B → $1.98B (+$221M)
0.27% less ownership
Funds ownership: 7.35% → 7.08% (-0.27%)
5% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 41
1% less funds holding
Funds holding: 313 → 309 (-4)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
13% less call options, than puts
Call options by funds: $57.8M | Put options by funds: $66.4M
24% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 100
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$33.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$16.1M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$8.43M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.6M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$7.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$67.5M |
| 2 |
PC
Paulson & Co
New York
|
-$31.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.4M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15.2M |
| 5 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$11.4M |
TAK Hedge Fund Activity: Q2 2020 in Review
309 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2020, worth a combined $1.98B — up 13% from $1.76B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of TAK and 39 opened new positions — a net loss of 2 holders — while 100 trimmed existing stakes and 76 added.
The largest buyer was Renaissance Technologies, adding an estimated $33.1M. The largest seller was Glenview Capital Management, cutting an estimated $67.5M.
- 309 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2020, down from 313 in Q1 2020.
- Funds reported $1.98B of Takeda Pharmaceutical stock for Q2 2020, up 13% quarter-over-quarter.
- 39 funds opened new Takeda Pharmaceutical positions in Q2 2020 and 41 closed out, a net change of -2 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2020 was Renaissance Technologies, an estimated $33.1M added.
- The largest Takeda Pharmaceutical seller in Q2 2020 was Glenview Capital Management, an estimated $67.5M sold.
Based on aggregated 13F filings for Q2 2020.